Kura Oncology, Inc. $KURA Shares Sold by Hsbc Holdings PLC

Hsbc Holdings PLC lessened its holdings in shares of Kura Oncology, Inc. (NASDAQ:KURA) by 60.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 52,003 shares of the company’s stock after selling 79,189 shares during the period. Hsbc Holdings PLC’s holdings in Kura Oncology were worth $536,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in KURA. Virtu Financial LLC acquired a new position in shares of Kura Oncology during the 4th quarter worth approximately $349,000. Invesco Ltd. increased its holdings in shares of Kura Oncology by 14.6% in the fourth quarter. Invesco Ltd. now owns 209,370 shares of the company’s stock valued at $2,175,000 after purchasing an additional 26,683 shares during the last quarter. Mercer Global Advisors Inc. ADV lifted its position in Kura Oncology by 52.3% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 50,080 shares of the company’s stock worth $520,000 after buying an additional 17,197 shares in the last quarter. Voloridge Investment Management LLC purchased a new position in Kura Oncology during the fourth quarter worth approximately $2,505,000. Finally, Virtus Investment Advisers LLC boosted its stake in Kura Oncology by 291.4% during the fourth quarter. Virtus Investment Advisers LLC now owns 66,870 shares of the company’s stock worth $695,000 after buying an additional 49,785 shares during the last quarter.

Insiders Place Their Bets

In other Kura Oncology news, insider Mollie Leoni sold 84,929 shares of the business’s stock in a transaction that occurred on Thursday, June 18th. The stock was sold at an average price of $9.82, for a total value of $834,002.78. Following the sale, the insider owned 182,345 shares of the company’s stock, valued at $1,790,627.90. The trade was a 31.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 7.60% of the company’s stock.

Analyst Ratings Changes

Several brokerages have issued reports on KURA. Weiss Ratings restated a “sell (d-)” rating on shares of Kura Oncology in a report on Tuesday, April 21st. Mizuho reduced their price target on Kura Oncology from $30.00 to $25.00 and set an “outperform” rating on the stock in a report on Tuesday, March 24th. CLSA set a $24.00 price target on shares of Kura Oncology in a research report on Thursday, June 4th. Cantor Fitzgerald reissued an “overweight” rating on shares of Kura Oncology in a report on Thursday, June 4th. Finally, Citizens Jmp restated a “market outperform” rating and set a $24.00 price objective on shares of Kura Oncology in a research report on Monday, June 15th. Ten equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $25.46.

Kura Oncology Price Performance

Shares of KURA opened at $10.89 on Friday. Kura Oncology, Inc. has a 1-year low of $5.45 and a 1-year high of $12.49. The stock has a market cap of $966.71 million, a PE ratio of -3.25 and a beta of 0.35. The firm has a 50-day simple moving average of $10.14 and a two-hundred day simple moving average of $9.26. The company has a debt-to-equity ratio of 0.09, a current ratio of 6.15 and a quick ratio of 6.14.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.83) EPS for the quarter, topping the consensus estimate of ($0.88) by $0.05. Kura Oncology had a negative net margin of 411.19% and a negative return on equity of 141.95%. The firm had revenue of $18.27 million for the quarter, compared to analyst estimates of $25.97 million. As a group, analysts forecast that Kura Oncology, Inc. will post -3.45 EPS for the current year.

Kura Oncology Company Profile

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.